RIBOCYGNUS Trademark

Trademark Overview


On Tuesday, June 16, 2026, a trademark application was filed for RIBOCYGNUS with the United States Patent and Trademark Office. The USPTO has given the RIBOCYGNUS trademark a serial number of 99888114. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, June 16, 2026. This trademark is owned by Suzhou Ribo Life Science Co., Ltd.. The RIBOCYGNUS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; Development services of drugs; pharmaceutical product evaluation; Research and development services of new pharmaceutical products; Research and development in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; Development of pharmaceutical preparations and medicines; Scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design

Medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders, nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders, nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders , nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders , nervo...
ribocygnus

General Information


Serial Number99888114
Word MarkRIBOCYGNUS
Filing DateTuesday, June 16, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateTuesday, June 16, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkRIBOCYGNUS
Goods and Servicestechnological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; Development services of drugs; pharmaceutical product evaluation; Research and development services of new pharmaceutical products; Research and development in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; Development of pharmaceutical preparations and medicines; Scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design
Pseudo MarkRIBO CYGNUS
Goods and ServicesMedicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders, nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders, nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders , nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders , nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; Biological preparations for use in cell cultures for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders, nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, renal diseases, liver diseases, genetic disorders, nervous system diseases and rare ocular, respiratory, gastrointestinal, cerebral disease; diagnostic preparations for medical purposes; Phosphates for pharmaceutical purposes; sodium salts for medical purposes; Pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the peripheral nervous system; antidepressants; antiepileptic pharmaceutical preparations; pain relief medication; balsamic preparations for medical purposes; pharmaceutical preparations for the treatment of infectious diseases; pharmaceuticals for the treatment of viral diseases; pharmaceutical preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; Anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; pharmaceuticals for ophthalmological use; nucleic acid sequences for medical and veterinary purposes; dietetic foods and beverages adapted for medical use; depuratives for the body; pesticides; Medical dressings; Composite materials for dental and dental technical purposes; cardiovascular agents for medical purposes; anti-diabetic preparations; Pharmaceutical agents affecting peripheral nervous system; analgesics; Analgesic preparation; Antivirals; pharmaceutical preparations for the treatment of viral diseases; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; Anti-cancer preparations; biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; antihypertensives; hypolipidemic agents; Cholesterol reducers; ophthalmological preparations; diapers for pets

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 16, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, June 16, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSuzhou Ribo Life Science Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressKunshan City, Jiangsu 215300
CN

Trademark Events


Event DateEvent Description
Tuesday, June 16, 2026NEW APPLICATION ENTERED
Tuesday, June 16, 2026APPLICATION FILING RECEIPT MAILED